173 related articles for article (PubMed ID: 16270637)
1. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
Schulman S; Lundström T; Wålander K; Billing Clason S; Eriksson H
Thromb Haemost; 2005 Oct; 94(4):820-4. PubMed ID: 16270637
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
[TBL] [Abstract][Full Text] [Related]
3. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
[TBL] [Abstract][Full Text] [Related]
4. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
Harenberg J; Jörg I; Weiss C
Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
[TBL] [Abstract][Full Text] [Related]
6. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
Wåhlander K; Eriksson H; Lundström T; Billing Clason S; Wall U; Nyström P; Wessman P; Schulman S;
Br J Haematol; 2006 Apr; 133(1):68-77. PubMed ID: 16512831
[TBL] [Abstract][Full Text] [Related]
7. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
Harenberg J; Ingrid J; Tivadar F
Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
9. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
Koscielny J; Kiesewetter H; Jörg I; Harenberg J
Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
[TBL] [Abstract][Full Text] [Related]
10. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
11. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Harenberg J; Jörg I; Weiss C
Eur J Clin Pharmacol; 2006 Mar; 62(3):173-7. PubMed ID: 16416154
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
13. The role of ximelagatran in the treatment of venous thromboembolism.
Schulman S
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
[TBL] [Abstract][Full Text] [Related]
14. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Halperin JL;
Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
[TBL] [Abstract][Full Text] [Related]
15. [Ximelagatran for treatment of venous thromboembolism].
Harenberg J; Fenyvesi T; Jörg I
Hamostaseologie; 2002 Aug; 22(3):25-9. PubMed ID: 12215758
[TBL] [Abstract][Full Text] [Related]
16. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
[TBL] [Abstract][Full Text] [Related]
17. Ximelagatran: an oral direct thrombin inhibitor.
Dager WE; Vondracek TG; McIntosh BA; Nutescu EA
Ann Pharmacother; 2004 Nov; 38(11):1881-97. PubMed ID: 15383641
[TBL] [Abstract][Full Text] [Related]
18. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
19. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
Mohapatra R; Tran M; Gore JM; Spencer FA
Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
